Raymond James Upgrades CME Group (CME) to Outperform

Go back to Raymond James Upgrades CME Group (CME) to Outperform

UBS Lowers Numbers on CME Group (CME) Post Q3, Maintains Buy on Upside Opportunity

October 26, 2012 12:43 PM EDT

UBS trimmed estimates and its price target on CME Group (NASDAQ: CME) from $66 to $64 but kept its Buy rating following third quarter results.

"We believe investors had overly optimistic expectations for the size of the fifth (sixth) dividend ($2.00+ per share) that... More

Evercore Partners Downgrades CME Group (CME) to Equal Weight

October 26, 2012 7:20 AM EDT

Evercore Partners downgraded CME Group (NASDAQ: CME) from Overweight to Equal Weight with a price target of $55.00 (from $60.00) after third quarter results.

NOTE: Shares were also upgraded today at another firm.

For an analyst ratings summary and ratings... More

CME Group, Inc. (CME) Misses Q3 EPS by 6c

October 25, 2012 9:15 AM EDT

CME Group, Inc. (NASDAQ: CME) reported Q3 EPS of $0.66, $0.06 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $683 million versus the consensus estimate of $701.5 million.

For earnings history and earnings-related data on CME Group, Inc. (CME) click here.... More